Comparative Pharmacology
Head-to-head clinical analysis: KARBINAL ER versus PROMETHAZINE WITH CODEINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KARBINAL ER versus PROMETHAZINE WITH CODEINE.
KARBINAL ER vs PROMETHAZINE WITH CODEINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbinoxamine is a first-generation antihistamine with anticholinergic and sedative properties. It competitively antagonizes histamine at H1 receptor sites, thereby alleviating symptoms of allergic reactions.
Promethazine is a phenothiazine derivative that antagonizes histamine at H1 receptors, acting as a sedative and antiemetic. Codeine is an opioid agonist at mu-opioid receptors, producing analgesia and antitussive effects via central nervous system depression.
Adults: 1-2 tablets (6-12 mg carbinoxamine) orally every 4-6 hours as needed; maximum 24 mg/day.
10-20 mg promethazine and 10-20 mg codeine (based on phosphate) orally every 4-6 hours as needed for cough; maximum daily codeine dose 120 mg.
None Documented
None Documented
Terminal elimination half-life ranges from 20 to 30 hours, supporting once-daily dosing in extended-release formulation.
Promethazine: 9-16 hours (mean 12 hours), clinically significant for sedation duration. Codeine: 2.5-4 hours (mean 3 hours), with active metabolite morphine 2-3 hours.
Renal (approximately 50% as unchanged drug and metabolites); fecal (approximately 40%); biliary (minor).
Promethazine: renal 70% as metabolites and unchanged drug, biliary/fecal 20-30%. Codeine: renal 90% (5-15% unchanged, rest as morphine and conjugates), fecal <10%.
Category C
Category A/B
Antihistamine
Antihistamine / Antiemetic